Akèy › Limfom Difize Gwo Selil B › Illinois
Etid klinik pou Limfom Difize Gwo Selil B nan Illinois
22 etid pou Limfom Difize Gwo Selil B ap chèche patisipan nan sit nan Illinois.
Vil nan Illinois
Tèks ofisyèl etid la (Anglè)
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Northwestern University, Chicago
- Northwestern Medicine Cancer Center Kishwaukee, DeKalb
- Northwestern Medicine Cancer Center Delnor, Geneva
- ak 6 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06649812A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Illinois Cancer Specialists ( Site 8000), Niles
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05139017A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- University of Chicago Medical Center ( Site 0126), Chicago
- Illinois Cancer Care ( Site 7005), Peoria
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06890884A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Edward Cancer Center ( Site 0197), Naperville
- Cancer Care Specialists of Illinois ( Site 0152), O'Fallon
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06717347A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- The University of Chicago Medical Center (UCMC), Chicago
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Cancer Care Specialists of Central Illinois, Swansea
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06806033Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
- University of Chicago Comprehensive Cancer Center, Chicago
- UC Comprehensive Cancer Center at Silver Cross, New Lenox
- University of Chicago Medicine-Orland Park, Orland Park
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT05272384Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Northwestern University - Feinberg School of Medicine, Chicago
- Rush University Medical Center, Chicago
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 31, 2026 · NCT06500273Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- City of Hope at Chicago, Zion
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07365306Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
- University of Chicago, Chicago
- Northwestern University, Evanston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07284433A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- University of Chicago Medical Center, Chicago
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT04104776Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- Robert H Lurie Cancer Center, Chicago
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06116110A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Northwestern, Chicago
- University of Chicago, Chicago
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Robert H Lurie Cancer Center, Chicago
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
- University of Illinois at Chicago, Chicago
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 10, 2026 · NCT05077527Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Northwestern University, Chicago
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 9, 2026 · NCT06015880A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Northwestern University, Chicago
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 2, 2026 · NCT05131022The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Illinois at Chicago Cancer Center, Chicago
Ap rekriteFaz 1/2
Laj 12 a 95 · Tout sèks · Mizajou Apr 15, 2026 · NCT04329728A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- The University of Chicago Medical Center, Chicago
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Mar 20, 2026 · NCT04830137Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Feb 2, 2026 · NCT05633615Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- Carle at The Riverfront, Danville
- ak 6 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 20, 2025 · NCT05890352A Study of NX-1607 in Adults With Advanced Malignancies
- University of Chicago, Chicago
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2025 · NCT05107674Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.